EUVIMEDEUVIMED entdecken
Fallbericht

The Dilemma of Edoxaban Interruption and Heparin Bridging Before Upgrading to Cardiac Resynchronization Therapy in an Older Patient with Atrial Fibrillation, Chronic Kidney Disease, and a Mitral Bioprosthesis

Mert Doğan, Uğur Canpolat

Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · 2026

DOI: 10.5543/tkda.2024.86907 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, 2026. Verfasst von Mert Doğan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Türkiye. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Bioprosthesis, Cardiac Resynchronization Therapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The peri-procedural management of novel oral anticoagulants (NOAC) should be individualized based on patient-specific factors (age, body weight, renal function, concomitant medications, history of thromboembolic or bleeding events, and the presence of prosthetic valve) as well as procedural characteristics (bleeding risk). Less invasive procedures carry a relatively low bleeding risk and may be performed with minimal or no interruption of NOAC therapy. However, upgrading from an implantable cardioverter-defibrillator (ICD) to cardiac resynchronization therapy (CRT) is more complex than initial implantation. Therefore, the timing of the last NOAC dose before an elective procedure requires careful judgment, balancing individual risks and benefits. Herein, we present the case of an elderly patient with atrial fibrillation, grade IIIb chronic renal disease, low body weight, and a bioprosthetic mitral valve, who underwent an upgrade from an implantable cardioverter-defibrillator (ICD) to cardiac resynchronization therapy with a defibrillator (CRT-D). The patient developed bioprosthetic valve thrombosis 24 hours after edoxaban interruption without heparin bridging, which was successfully treated with ultraslow tissue plasminogen activator (tPA) therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAtrial FibrillationBioprosthesisCardiac Resynchronization TherapyFactor Xa InhibitorsHeart Valve ProsthesisHeparinHumansMaleMitral ValvePyridinesRenal Insufficiency, ChronicThiazolesThrombosisAged, 80 and over

Substanzen

AnticoagulantsedoxabanFactor Xa InhibitorsHeparinPyridinesThiazoles

Autor:innen und Institutionen

  • Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Türkiye.

Zitieren

APA

Doğan, M., & Canpolat, U. (2026). The Dilemma of Edoxaban Interruption and Heparin Bridging Before Upgrading to Cardiac Resynchronization Therapy in an Older Patient with Atrial Fibrillation, Chronic Kidney Disease, and a Mitral Bioprosthesis. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology. https://doi.org/10.5543/tkda.2024.86907

Vancouver

Doğan M, Canpolat U. The Dilemma of Edoxaban Interruption and Heparin Bridging Before Upgrading to Cardiac Resynchronization Therapy in an Older Patient with Atrial Fibrillation, Chronic Kidney Disease, and a Mitral Bioprosthesis. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology. 2026. doi:10.5543/tkda.2024.86907

BibTeX
@article{Doan2026,
  author = {Doğan, Mert and Canpolat, Uğur},
  title = {The Dilemma of Edoxaban Interruption and Heparin Bridging Before Upgrading to Cardiac Resynchronization Therapy in an Older Patient with Atrial Fibrillation, Chronic Kidney Disease, and a Mitral Bioprosthesis},
  journal = {Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology},
  year = {2026},
  doi = {10.5543/tkda.2024.86907}
}
Kostenlos starten →